Scarica l'app Stockscreener
32.03
3.58%
-1.19
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RARE Giù?
Forum
Previsione
Frazionamento azionario
Ultragenyx Pharmaceutical Inc Borsa (RARE) Ultime notizie
Wedbush Raises Price Target on Ultragenyx Pharmaceutical to $30 From $26, Keeps Neutral Rating - Moomoo
RARE Stock Edges Up On Priority Review For Gene Therapy In Rare Metabolic Disorder - Stocktwits
Ultragenyx Pharmaceutical (RARE) Is Up 7.4% After Index Migration To Russell 2000 And Value BenchmarksHas The Bull Case Changed? - Sahm
(RARE) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Ultragenyx releases 2025 impact report on rare disease work By Investing.com - Investing.com South Africa
Ultragenyx releases 2025 impact report on rare disease work - Investing.com
Ultragenyx Releases 2025 Impact Report Emphasizing Commitment to Rare Disease Patients, Innovation, and Global Impact - The Manila Times
Ultragenyx Releases 2025 Impact Report Highlighting Progress in Rare Disease Therapies, Patient Access and Sustainability - Quiver Quantitative
Ultragenyx Releases 2025 Impact Report Emphasizing - GlobeNewswire
Ultragenyx says five rare-disease programs reached pivotal trials in 2025 - Stock Titan
RBC Capital Adjusts Ultragenyx Pharmaceutical Price Target to $40 From $35, Maintains Outperform Rating - Moomoo
RBC Capital Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Raises Target Price to $40 - Moomoo
Ultragenyx CFO Howard Horn sells $155,644 in company shares By Investing.com - Investing.com South Africa
Form 4 Ultragenyx For: 6 July By Investing.com - Investing.com South Africa
Ultragenyx CFO Howard Horn sells $155,644 in company shares - Investing.com
Ultragenyx (RARE) CFO sells 4,698 shares, retains 100,991 stake - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) Shift From Loss To Profit - 富途牛牛
RAREUltragenyx Pharmaceutical Inc Latest SEC Filings - Finviz
Form 144 ULTRAGENYX PHARMACEUTICAL INC. For: 1 July By Investing.com - Investing.com Canada
RARE (NASDAQ: RARE) affiliate reports insider sales and scheduled awards - Stock Titan
RARE DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Ultrage - The National Law Review
Ultragenyx Pharmaceutical Inc. (RARE) Investigation: Bronstein, G - The National Law Review
Ultragenyx 48 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds - The National Law Review
Does Ultragenyx (RARE) Shifting Into Small‑Cap Value Indices Recast Its Rare‑Disease Growth Story? - simplywall.st
Ultragenyx Pharmaceutical Inc.(NasdaqGS: RARE) added to Russell 2000 Index - marketscreener.com
Ultragenyx Pharmaceutical Inc.(NasdaqGS:RARE) dropped from Russell Midcap Growth Benchmark - marketscreener.com
Ultragenyx Pharmaceutical Inc.(NasdaqGS:RARE) added to Russell 2000 Value Benchmark - marketscreener.com
Ultragenyx (RARE) Soars 5.2%: Is Further Upside Left in the Stock? - Yahoo Finance
Ultragenyx Pharmaceutical Inc.(NasdaqGS:RARE) added to Russell 2000 Growth Benchmark - marketscreener.com
Ultragenyx Pharmaceutical Inc.(NasdaqGS:RARE) dropped from Russell 1000 Growth Benchmark - marketscreener.com
Price to book forward of Ultragenyx Pharmaceutical Inc. – NASDAQ:RARE - TradingView
Ultragenyx Pharmaceutical Inc.(NasdaqGS:RARE) dropped from Russell 1000 Dynamic Index - marketscreener.com
Ultragenyx Pharmaceutical Inc.(NasdaqGS: RARE) dropped from Russell Midcap Index - marketscreener.com
Ultragenyx Pharmaceutical Inc.(NasdaqGS: RARE) dropped from Russell 1000 Index - marketscreener.com
Ultragenyx Pharmaceutical Inc.(NasdaqGS: RARE) added to Russell 2000 Dynamic Index - marketscreener.com
RARE Stock Slumps On Multiple Wall Street Price Target Slashes, Clinical Pipeline Uncertainty - Stocktwits
Enterprise value to revenue forward of Ultragenyx Pharmaceutical Inc. – NASDAQ:RARE - TradingView
Enterprise value to EBIT forward of Ultragenyx Pharmaceutical Inc. – NASDAQ:RARE - TradingView
Ultragenyx Pharmaceutical Inc.(NasdaqGS:RARE) added to Russell 3000E Value Benchmark - marketscreener.com
Price to sales forward of Ultragenyx Pharmaceutical Inc. – NASDAQ:RARE - TradingView
Price to earnings forward of Ultragenyx Pharmaceutical Inc. – NASDAQ:RARE - TradingView
Ultragenyx Pharmaceutical, Inc. Actuals & Estimates (NASDAQ:RARE) - TradingView
Ultragenyx Pharmaceutical, Inc. Actuals & Estimates (BX:UP0) - TradingView
RARE Forecast — Price Target — Prediction for 2027 - TradingView
Ultragenyx: The Setrusumab Reset Creates A Cleaner Rare Disease Opportunity - Seeking Alpha
Ultragenyx Pharmaceutical Inc. $RARE Shares Bought by Caitong International Asset Management Co. Ltd - MarketBeat
Ultragenyx grants 44,409 restricted stock units to 15 new non-executive officers as an inducement. - Pluang
Ultragenyx awards 44,409 RSUs to 15 new hires - Stock Titan
0.89%
1.38%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):